SGMO Sangamo Therapeutics, Inc. Stock Quote

SGMO [NASD]

Index	-	P/E	-	EPS (ttm)	-1.26	Insider Own	17.01%	Shs Outstand	145.40M	Perf Week	-10.56%
Market Cap	842.24M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-1.10%	Shs Float	120.90M	Perf Month	-22.28%
Income	-181.40M	PEG	-	EPS next Q	-0.34	Inst Own	53.10%	Short Float	7.39%	Perf Quarter	-30.64%
Sales	108.50M	P/S	7.76	EPS this Y	-6.00%	Inst Trans	0.03%	Short Ratio	5.96	Perf Half Y	-41.69%
Book/sh	2.79	P/B	2.13	EPS next Y	-5.30%	ROA	-21.20%	Target Price	18.89	Perf Year	-61.86%
Cash/sh	2.98	P/C	1.99	EPS next 5Y	-	ROE	-39.90%	52W Range	6.03 - 16.79	Perf YTD	-20.93%
Dividend	-	P/FCF	-	EPS past 5Y	-9.10%	ROI	-26.10%	52W High	-64.68%	Beta	1.51
Dividend %	-	Quick Ratio	3.40	Sales past 5Y	24.50%	Gross Margin	-	52W Low	-1.66%	ATR	0.45
Employees	413	Current Ratio	3.40	Sales Q/Q	-50.50%	Oper. Margin	-	RSI (14)	27.71	Volatility	6.07% 5.95%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.00	Prev Close	6.40
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 BMO	Payout	-	Avg Volume	1.50M	Price	5.93
Recom	2.10	SMA20	-20.62%	SMA50	-29.02%	SMA200	-39.42%	Volume	1,503,372	Change	-7.34%

May-04-21

Initiated

RBC Capital Mkts

Outperform

$22

Jan-07-21

Resumed

Guggenheim

Neutral

$16

Jan-06-21

Initiated

Stifel

Hold

$16

Dec-16-20

Resumed

H.C. Wainwright

Buy

$25

Sep-08-20

Initiated

BofA Securities

Buy

$20

Jul-07-20

Initiated

SunTrust

Buy

$22

Aug-26-19

Initiated

H.C. Wainwright

Buy

$16

Nov-14-18

Downgrade

JP Morgan

Overweight → Neutral

Nov-09-18

Downgrade

Guggenheim

Buy → Neutral

Oct-10-18

Initiated

Guggenheim

Buy

Jun-20-18

Initiated

BofA/Merrill

Buy

$24

Nov-15-17

Upgrade

Piper Jaffray

Neutral → Overweight

Jun-22-17

Resumed

Jefferies

Buy

$17

Nov-01-16

Downgrade

Wedbush

Outperform → Neutral

$30 → $4

Oct-19-16

Downgrade

Piper Jaffray

Overweight → Neutral

Dec-04-15

Initiated

Wells Fargo

Outperform

Oct-23-15

Resumed

Jefferies

Buy

May-03-13

Initiated

BioLogic Equity Research

Sell

Feb-23-11

Reiterated

JMP Securities

Mkt Outperform

$9 → $12

Jul-29-10

Reiterated

Wedbush

Outperform

$12 → $13

Jan-13-22 01:38PM	McGuire Investment Group, LLC Buys SPDR Bloomberg 1-3 Month T-Bill ETF, WisdomTree Floating ... GuruFocus.com
Jan-06-22 08:00AM	Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo Business Wire
Jan-04-22 05:00PM	Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference Business Wire -5.12%
Dec-20-21 05:29PM	BioMarin settles trade secrets 'misunderstanding' with former employee American City Business Journals
Dec-13-21 10:54AM	Pfizer (PFE) Gets Approval for New Eczema Drug in Europe Zacks -5.69%
Dec-12-21 04:30PM	Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy Business Wire
09:00AM	Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease Business Wire
Dec-10-21 09:34AM	Investors in Sangamo Therapeutics (NASDAQ:SGMO) have made a strong return of 139% over the past five years Simply Wall St. -5.04%
Nov-22-21 07:00AM	Organogenesis Appoints Prathyusha Duraibabu to Board of Directors GlobeNewswire
Nov-18-21 05:54PM	BioMarin says ex-employee downloaded trade secrets. He says it's a misunderstanding. American City Business Journals
Nov-09-21 08:30AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Nov-08-21 10:13AM	Wall Street Analysts Think Sangamo (SGMO) Could Surge 64%: Read This Before Placing a Bet Zacks
Nov-04-21 10:01PM	Sangamo Therapeutics, inc (SGMO) Q3 2021 Earnings Call Transcript Motley Fool +19.15%
05:20PM	Why Did Sangamo Stock Jump 20% Today? Benzinga
10:25AM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates Zacks
09:05AM	Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results Business Wire
08:00AM	Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated -Gal A Enzyme Activity in Patients With Fabry Disease Business Wire
Oct-28-21 04:30PM	Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast Business Wire
Oct-27-21 03:03PM	Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to Decline Zacks
Oct-11-21 03:29PM	Could The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ownership Structure Tell Us Something Useful? Simply Wall St.
Aug-31-21 08:30AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Aug-10-21 05:21AM	Sangamo Therapeutics (NASDAQ:SGMO) Is In A Strong Position To Grow Its Business Simply Wall St.
Aug-09-21 04:30PM	Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference Business Wire
Aug-05-21 05:45PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates Zacks +5.39%
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results Business Wire
Jul-30-21 12:15PM	Were Hedge Funds Right About Selling Sangamo Therapeutics, Inc. (SGMO)? Insider Monkey
Jul-29-21 04:30PM	Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast Business Wire
Jul-28-21 03:03PM	Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to Decline Zacks
Jun-14-21 11:51AM	RBC Capital: 3 Stocks to Buy With Over 50% Upside Potential TipRanks
Jun-07-21 10:22AM	Did You Miss Sangamo Therapeutics' (NASDAQ:SGMO) 69% Share Price Gain? Simply Wall St.
May-24-21 04:15PM	Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer Business Wire
May-21-21 08:30AM	Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference Business Wire
May-12-21 01:52PM	Wasatch Global on Sangamo (SGMO): We Remain Optimistic About its Future Prospects Insider Monkey
May-05-21 05:01AM	Sangamo Therapeutics Inc (SGMO) Q1 2021 Earnings Call Transcript Motley Fool -8.54%
May-04-21 05:25PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results Business Wire
03:15PM	Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-21 04:30PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Apr-27-21 04:30PM	Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy Business Wire
04:15PM	Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast Business Wire
Mar-25-21 08:30AM	Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease Business Wire +6.14%
Mar-17-21 04:30PM	Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease Business Wire
Mar-16-21 03:26PM	Wells Fargo: 2 Compelling Stocks With Over 70% Upside Potential TipRanks
Mar-09-21 05:10AM	What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Registry? Simply Wall St. +5.88%
Mar-01-21 11:10AM	Is Sangamo Therapeutics (SGMO) Stock a Buy For 2021? Insider Monkey
Feb-26-21 09:34AM	Stock Market News for Feb 26, 2021 Zacks
Feb-25-21 06:30PM	Sangamo Therapeutics Inc (SGMO) Q4 2020 Earnings Call Transcript Motley Fool -10.62%
Feb-24-21 04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results Business Wire
03:15PM	Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 04:15PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Feb-17-21 04:15PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast Business Wire
Feb-01-21 04:05PM	Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer Business Wire
Jan-07-21 11:25PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Just Slashed Next Year's Estimates Simply Wall St.
Jan-06-21 04:10PM	Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee Business Wire
Jan-05-21 08:00AM	Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-15-20 10:54AM	Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5% Zacks
10:40AM	Sangamo Therapeutics Sees RS Rating Rise To 85 And Composite Rating At 81 Investor's Business Daily
Dec-14-20 08:43AM	Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock? Zacks +6.51%
Dec-10-20 02:03PM	CRISPR Gene Editing: Owning the Future of Medicine Zacks +52.98%
Dec-07-20 07:00AM	Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy Business Wire -7.11%
Nov-30-20 06:42AM	How Much Did Sangamo Therapeutics'(NASDAQ:SGMO) Shareholders Earn From Share Price Movements Over The Last Three Years? Simply Wall St.
Nov-24-20 11:39AM	Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate Zacks
Nov-05-20 08:00AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Nov-04-20 11:02PM	Sangamo Therapeutics Inc (SGMO) Q3 2020 Earnings Call Transcript Motley Fool +10.99%
05:45PM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results Business Wire
03:15PM	Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 04:15PM	Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast Business Wire
12:32PM	Will Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-16-20 11:36AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Insiders Increased Their Holdings Simply Wall St.
Oct-07-20 06:45AM	Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment Business Wire
Oct-05-20 11:41AM	Is Sangamo Therapeutics, Inc. (SGMO) A Good Stock To Buy? Insider Monkey +5.96%
Sep-28-20 08:30AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Sep-15-20 10:48AM	Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Sep-11-20 08:30AM	Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors Business Wire
Sep-10-20 12:11PM	Sangamo Therapeutics Getting Closer To Key Technical Benchmark Investor's Business Daily
Sep-02-20 04:15PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire
Sep-01-20 03:47PM	How Much Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Paying Its CEO? Simply Wall St. -9.42%
Aug-20-20 09:43AM	BioMarin Stocks Near-Term Growth Is Gone, Analyst Says. Heres Why. Barrons.com
Aug-19-20 12:19PM	BioMarin Stock Slumps After FDAs Surprise Rejection of a Hemophilia Gene Therapy Barrons.com
Aug-10-20 08:30AM	Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference Business Wire
Aug-05-20 06:35PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM	Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results Business Wire
Aug-03-20 12:49PM	Did Hedge Funds Make The Right Call On Sangamo Therapeutics, Inc. (SGMO) ? Insider Monkey +6.56%
Jul-30-20 07:00AM	Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders Business Wire +14.55%
Jul-29-20 04:15PM	Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast Business Wire
12:33PM	Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy? Zacks
Jul-27-20 06:07PM	4 More Biotechs Break From IPO Starting Gate GuruFocus.com
Jul-09-20 07:43AM	How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Do Institutions Own? Simply Wall St.
07:31AM	3 Top Biotech Stocks to Watch in July Motley Fool
Jun-24-20 08:00AM	Sangamo Announces R&D Organization Changes Business Wire -5.20%
Jun-19-20 12:22PM	Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO) Insider Monkey -6.37%
Jun-18-20 09:44AM	Pfizer's hemophilia gene therapy shows sustained effect in early-stage study Reuters -13.18%
09:01AM	Pfizer's hemophilia gene therapy shows sustained effect in early-stage study Reuters
09:00AM	Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy Business Wire
Jun-16-20 08:36AM	Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock? Zacks
Jun-15-20 10:40PM	Edited Transcript of SGMO.OQ earnings conference call or presentation 11-May-20 9:00pm GMT Thomson Reuters StreetEvents
Jun-14-20 06:00AM	Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Jun-11-20 05:14PM	Sangamo Stock Avoids Biotech Pitfall On Pfizer-Partnered Gene Therapy Investor's Business Daily
May-29-20 09:00AM	Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference Business Wire

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOGEN INC.	10% Owner	Dec 28	Sale	8.51	2,764	23,522	24,152,466	Dec 30 05:12 PM
BIOGEN INC.	10% Owner	Dec 27	Sale	8.56	600	5,136	24,155,230	Dec 28 08:11 AM
BIOGEN INC.	10% Owner	Dec 23	Sale	8.55	81,187	694,530	24,155,830	Dec 28 08:11 AM
BIOGEN INC.	10% Owner	Dec 09	Sale	8.56	23,660	202,541	24,237,017	Dec 10 04:08 PM
BIOGEN INC.	10% Owner	Dec 08	Sale	8.64	75,814	654,828	24,260,677	Dec 09 04:08 PM
BIOGEN INC.	10% Owner	Dec 07	Sale	8.52	52,178	444,437	24,336,491	Dec 09 04:08 PM
BIOGEN INC.	10% Owner	Dec 02	Sale	8.51	1,874	15,943	24,388,669	Dec 03 04:09 PM
BIOGEN INC.	10% Owner	Dec 01	Sale	8.52	730	6,223	24,390,543	Dec 03 04:09 PM
BIOGEN INC.	10% Owner	Nov 26	Sale	8.60	28,884	248,434	24,391,273	Nov 30 04:20 PM
LOEB GARY	EVP, General Counsel & Sec.	Mar 23	Option Exercise	11.02	11,981	132,031	100,762	Mar 25 07:19 PM
LOEB GARY	EVP, General Counsel & Sec.	Mar 23	Sale	13.13	17,524	230,042	83,238	Mar 25 07:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience